EGFR protein: A systematic analysis from domain conformation to drug resistance mechanisms

This article focuses on the molecular characteristics and signaling regulation mechanisms of the epidermal growth factor receptor (EGFR), systematically elaborating the domain composition of its transmembrane glycoprotein structure as a member of the HER1/ERBB family and the conformational differences between its active and inactive states, analyzing how ligand-induced dimerization and tyrosine autophosphorylation initiate the RAS/RAF-MAPK and PI3K-AKT-mTOR downstream signaling axes, and exploring the diversity of acquired resistance mechanisms such as EGFR secondary mutations, bypass activation, and alterations in downstream pathway components.

  • Recent Advances
  • Product Information
Recent Advances

 

EGFR Protein: A Systematic Analysis from Domain Conformation to Resistance Mechanisms
Summary: This article focuses on the molecular characteristics and signal regulatory mechanisms of the epidermal growth factor receptor (EGFR), systematically describing its domain composition as a transmembrane glycoprotein and member of the HER1/ERBB family, as well as the conformational differences between its active and inactive states. It analyzes how ligand-induced dimerization and tyrosine autophosphorylation initiate the downstream signaling axes of RAS/RAF-MAPK and PI3K-AKT-mTOR, and discusses the diversity of acquired resistance mechanisms, including secondary EGFR mutations, bypass activation, and alterations in downstream pathway components.
I. Molecular Identity and Tissue Distribution of EGFR.
The epidermal growth factor receptor is a receptor tyrosine kinase, also known as HER1 or ERBB. EGFR is a cell surface protein that can bind to epidermal growth factor, thereby inducing receptor dimerization and tyrosine autophosphorylation, which in turn leads to cell proliferation. EGFR mutations or overexpression generally trigger tumors, such as non-small cell lung cancer. In terms of tissue distribution, EGFR is widely distributed on the surface of mammalian epithelial cells, fibroblasts, glial cells, keratinocytes, and other cells. The EGFR signaling pathway plays an important role in physiological processes such as cell growth, proliferation, and differentiation. This broad expression pattern across cells of epithelial and mesenchymal origin is consistent with its physiological functions in tissue repair and homeostasis maintenance, and also explains why dysregulated EGFR signaling can drive tumorigenesis in multiple tissue types.
II. Protein Structure and Functional Domain Division of EGFR.
EGFR is a transmembrane glycoprotein with a molecular weight of approximately 170 kDa, composed of a cysteine-rich extracellular ligand-binding domain, a hydrophobic transmembrane domain, a cytoplasmic receptor tyrosine kinase domain, and a C-terminal domain. In the extracellular region, L1 and L2 are the receptor ligand-binding sites, while CR1 and CR2 are rich in cysteine residues and responsible for dimerization between receptors. The intracellular structure contains one tyrosine kinase domain and a carboxyl-terminal tail with multiple autophosphorylation sites. The target of small-molecule EGFR tyrosine kinase inhibitors is the intracellular domain, and multiple mutations within the tyrosine kinase domain are associated with resistance and sensitivity to EGFR-TKIs. This division of labor—“extracellular domain responsible for ligand recognition and dimerization, intracellular domain responsible for catalysis and signal output”—determines that EGFR activation is a transmembrane process requiring coordinated extracellular conformational changes and intracellular catalytic activity, and also determines the fundamental mechanistic differences between intervention approaches targeting different domains (antibodies acting on the extracellular domain, small molecules acting on the intracellular domain).
III. Conformational Regulation of the Active and Inactive States of EGFR.
When EGFR is in the active state, within the tyrosine kinase domain, the critical catalytic residue D855 is located at the ATP-binding site, stabilizing the ATP-loaded complex and the αC helix. In the inactive state, EGFR adopts a Src-like structure, including a closed A-loop, αC-out, and DFG-in. This description of conformational states—“αC-in versus αC-out, DFG-in”—is the structural language for understanding how kinase inhibitors selectively bind to different conformational states: first- and second-generation reversible inhibitors tend to bind the active conformation, while some irreversible inhibitors lock specific conformations through covalent bonds. Therefore, the conformational equilibrium of the kinase domain is not only a switch for physiological regulation but also the structural basis for selectivity in drug design and for resistance mechanisms.
IV. Ligand-Induced Activation of EGFR and Downstream Signaling Axes.
The binding of EGFR to specific ligands such as EGF and TGF-α leads to homo- or heterodimerization of the receptor, which in turn causes conformational changes in the intracellular kinase domain, leading to receptor phosphorylation and activation. The signaling axes RAS/RAF-MAPK and PI3K-AKT-mTOR sequentially activate various downstream signaling pathways, thereby enhancing cell proliferation and survival. From the perspective of the signaling chain, ligand binding-induced dimerization is the initiating event, kinase domain conformational change and autophosphorylation are key nodes, and phosphorylated tyrosine residues serving as docking sites to recruit downstream effector proteins are the hub of signal branching. The synergy of the two downstream pathways enables EGFR signaling to simultaneously support both proliferation and survival phenotypes, which also explains why inhibition of a single pathway is often insufficient to completely block EGFR-driven tumor growth.
V. Diversity of Acquired Resistance Mechanisms to EGFR.
The resistance mechanisms of EGFR mainly include secondary mutations in the EGFR gene such as the T790M mutation and C797S mutation, as well as other EGFR mutations such as L718Q, L796S, and L792H mutations and exon 20 insertions. They also include MET amplification, phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit α mutations, HER2 amplification, oncogene fusions, and alterations in cell cycle-related genes. Amplification and mutation of receptor tyrosine kinases can both induce downstream survival signaling pathways; in addition, direct overexpression and/or mutation of downstream pathway components can promote acquired resistance by enhancing cancer cell survival. Summarized at the mechanistic level, these resistance pathways can be divided into three categories: secondary mutations in the target itself that impede drug binding, amplification or activation of bypass receptor tyrosine kinases that bypass the EGFR node, and constitutive activation of downstream pathway components that renders signal output independent of the upstream receptor. The coexistence of these three types of mechanisms determines that treatment strategies after resistance must be based on molecular diagnosis of the specific resistance mechanism, rather than simply switching to another drug of the same class.
VI. Conclusion.
As a transmembrane glycoprotein of the HER1/ERBB family widely distributed in cells of epithelial and mesenchymal origin, EGFR constitutes the structural and mechanistic foundation of tumor-targeted therapy through its structural division—comprising the extracellular L1/L2 ligand-binding domains and CR1/CR2 dimerization domains, the transmembrane domain, the intracellular tyrosine kinase domain, and C-terminal autophosphorylation sites—its conformational regulation between the active state, in which D855 stabilizes the ATP-loaded complex and the αC-in conformation, and the inactive state with the Src-like αC-out conformation, and its signaling logic of driving cell proliferation and survival through the dual RAS/RAF-MAPK and PI3K-AKT-mTOR pathways following ligand-induced dimerization.
VII. Frequently Asked Questions on EGFR Binding Activity Detection and Product Information
To facilitate researchers and drug development teams in searching for evaluation schemes and product information regarding EGFR interactions, this section answers common questions about EGFR binding activity detection in a Q&A format and presents the product positioning and application scenarios of Biotinylated EGFR His&Avi Tag Protein, Human.
Q1: What methods are used to detect the binding activity of EGFR?
EGFR activation depends on ligand-induced dimerization and intracellular kinase autophosphorylation, so its in vitro evaluation typically focuses on the direct binding of ligands (such as EGF and TGF-α) or targeted drugs to the EGFR extracellular domain. Currently, in vitro methods for evaluating this interaction mainly include enzyme-linked immunosorbent assay (ELISA), surface plasmon resonance (SPR), and biolayer interferometry (BLI), as well as homogeneous detection systems based on streptavidin capture. Among these, ELISA and SPR/BLI can directly quantify the binding affinity of ligands or antibodies to the EGFR extracellular domain and are commonly used for ligand characterization and early screening of antibody drugs.
Q2: What are the advantages of biotinylated EGFR in binding experiments?
Biotinylated proteins can achieve oriented immobilization and efficient capture via the streptavidin-biotin system: the binding affinity between streptavidin and biotin is extremely high, and site-specific biotinylation mediated by the Avi tag ensures uniform distribution of biotin on each receptor molecule, avoiding interference with the ligand-binding interface caused by random labeling. This design enables EGFR to be immobilized in a controlled orientation on SPR chips, ELISA plates, or in TR-FRET systems, making it suitable for ligand binding kinetics measurements and competitive blocking experiments.
Q3: What is Biotinylated EGFR His&Avi Tag Protein, Human?
Biotinylated EGFR His&Avi Tag Protein, Human (Catalog No. UA010673) is a human-derived recombinant EGFR protein provided by UA-Bio, expressed in the HEK293 expression system, with the expressed sequence Leu25-Ser645 (Accession: P00533-1), carrying C-terminal His and Avi dual tags, and subjected to site-specific biotinylation. The endotoxin content of this product is less than 0.1 EU/μg, making it suitable for binding activity analysis of EGFR with ligands and targeted antibodies, research on the conformation of the EGFR tyrosine kinase domain and inhibitor binding mechanisms, and screening and activity evaluation of EGFR-targeted drugs.
Q4: What experimental scenarios is this product suitable for?
The main application scenarios of this product include: binding activity analysis and EC50 determination of EGFR with ligands such as EGF and TGF-α; binding activity evaluation of anti-EGFR monoclonal antibodies (such as cetuximab and necitumumab); in vitro screening of small-molecule tyrosine kinase inhibitors targeting EGFR; protein-protein interaction detection based on the streptavidin platform (such as SPR, BLI, and TR-FRET); and parallel comparison of binding activity among different ligands, antibodies, or protein batches.
Q5: What are the features of the His and Avi dual-tag design in experiments?
The His tag facilitates efficient purification via immobilized metal affinity chromatography and enables detection with anti-His antibodies; the Avi tag provides a substrate for BirA enzyme-mediated site-specific biotinylation, allowing biotin to be attached to a specific position on the protein in a uniform and controllable manner. The combined advantage of the dual-tag design is that the two steps of purification and labeling can be optimized independently, and site-specific biotinylation avoids the activity loss that may be caused by random chemical labeling. For receptors such as EGFR, whose ligand recognition is mediated by the extracellular domain, this design provides a reliable reagent foundation for highly sensitive detection of receptor-ligand interactions.
Product Information at a Glance
Product Name Biotinylated EGFR His&Avi Tag Protein, Human (Catalog No.: UA010673)
Brand UA-Bio
Molecular Aliases ERBB, ERBB1, HER1
Accession P00533-1
Expressed Sequence Leu25-Ser645, with C-terminal His&Avi tag
Expression System HEK293
Molecular Weight 95-110 kDa
Endotoxin Content <0.1 EU/μg
Tags Avi Tag, His Tag
Molecular Label Biotin
Form Lyophilized Powder
Buffer System PBS, pH7.4
Reconstitution Method After brief centrifugation, reconstitute with ultrapure water to 0.1-1 mg/mL according to the specification
Storage Conditions Lyophilized powder stored at -20 to -80°C, stable for 12 months from the date of receipt; after reconstitution, store under sterile conditions at -20 to -80°C for 3 months, or at 2 to 8°C for 1 week; avoid repeated freeze-thaw cycles
Core Applications Quantitative binding activity analysis, ligand/antibody screening and evaluation, kinase domain conformation research, streptavidin platform detection
Common Search Terms EGFR binding activity detection, Biotinylated EGFR, EGFR antibody screening, EGFR ligand binding, EGFR biotinylated protein, UA010673, UA-Bio UniOne
To conduct EGFR binding activity detection or receptor-ligand interaction research based on the streptavidin platform, search for the full product name “Biotinylated EGFR His&Avi Tag Protein, Human” or the catalog number “UA010673” in the UA-Bio Product Center to obtain product manuals, experimental protocols, and information on supporting reagents.

This article is reviewed and published by the technical expert team of UA

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

Purchase recombinant protein, choose

UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Nanjing Univ is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.

Target proteins | membrane proteins | cytokines | enzymes | viral antigens | protein customization
Buy antibodiesFind UA www.ua-bio.com | 15 years of protein development experience
Nanjing UNIV Biotechnology Co., Ltd. Email:order@ua-bio.com Phone:+86-25-56221161
公众号
Product Information
The Last The Next